Buying guide
Lingo vs Whoop (5.0 / MG) in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Abbott | Whoop |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $199-$359/year lease (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Abbott | 1Whoop |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 13data-retention, third-party-sharing, data-sale, third-party-sharing, biometric-storage, training-data-use, data-deletion-control, third-party-sharing, location-tracking, data-sale, data-deletion-control, data-retention, biometric-storage |
| Sources on file | 8 | 20 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Whoop (5.0 / MG)
Whoop (the 5.0 and the 'Medical Grade' MG, both launched May 8, 2025, from Whoop, founded 2012 in Boston by Will Ahmed) is a screen-free biometric wrist band and the subscription-only archetype of the biometric cohort: there is no standalone hardware sale. Access is a membership, Whoop One at $199/year, Peak at $239/year, and Life at $359/year (which includes the MG hardware), with the band provided inside the subscription. Its PPG, skin-temperature, SpO2, and respiratory sensors feed Strain, Recovery, and Sleep Coach analytics and an LLM 'Whoop Coach'; the MG adds ECG, Blood Pressure Insights, and a Healthspan / 'Whoop Age' feature. DEPLOY records commercial maturity and a reported $10.1 billion valuation (March 2026). Whoop is the strongest verified-vs-claimed cautionary exemplar in the cohort: its ECG is FDA-cleared (2025), but it marketed Blood Pressure Insights without clearance, drew an FDA Warning Letter on July 14, 2025, refused to remove the feature, and as of May 2026 the matter is unresolved with a class action filed, the market-first contrast to Oura's study-first posture.
Machine-readable: this page as markdown.